News

• Interim Report Second Quarter 2024, April 1 – June 30, Kancera AB (publ.), org.no. 556806-8851

  23 August 2024

• Kancera’s FRACTAL study results to be presented at the ESC 2024 Conference

  18 July 2024

• Phase Ib completed and the recommended phase II dose is set in the ongoing KANDOVA study

  11 July 2024

• Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

  17 May 2024

• Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment

  16 May 2024

• Kancera appoints new Chief Scientific Officer and extends management team

  8 May 2024

• Kancera meets the primary objectives of the KAND145 clinical phase I study

  3 May 2024

• Kancera announces the outcome of the company’s rights issue

  20 March 2024

• Kancera publishes prospectus in connection with the company’s rights issue

  1 March 2024

• Kancera resolves on a rights issue of approximately SEK 121.9 million

  23 February 2024